Business Wire

The Paper Packaging Industry Gears up for New Challenges In 2023

Share

The European Paper Packaging Alliance (EPPA) has this week welcomed a new President and Director General.

At EPPA’s General Assembly on 9 January, Antonio D’Amato, CEO of Seda International Packaging Group and former president of Confindustria, the Confederation of Italian Industry, has been elected President. He took over from Eric Le Lay, President of Huhtamaki Fibre Food Service who is now Vice-President of the Alliance.

EPPA also appointed Matti Rantanen, an experienced packaging expert and public affairs professional, as its new Director General.

2023 will be a pivotal year for the European packaging industry as discussions on the EU’s proposed Packaging and Packaging Waste Regulation heat up. The European Commission is proposing the mass implementation of reusable packaging across a range of sectors - in spite of life cycle analysis clearly showing it to be the least sustainable choice. EPPA will be making the case for the best environmental, renewable and recyclable single-use paper packaging.

Incoming EPPA President Antonio D'Amato said:

"I am honoured to take on the Presidency of EPPA again and thank all its members, particularly Eric Le Lay, for their excellent work over the past year. EPPA increasingly represents the leading companies in Europe’s paper packaging supply chain, from forest, paper and board producers to converters and brand owners as well. We will maintain our focus on continuing the innovative, sustainable development of single-use paper packaging that is fully integrated in the circular economy.

Our mission is increasingly focused on supporting policymakers to make decisions based on solid scientific evidence. Single-use paper packaging has an essential role to play in reducing CO2 emissions while simultaneously reducing food waste, avoiding water stress and protecting consumer health."

Eric Le Lay, President of Fiber & Foodservice at Huhtamaki and Vice-President of EPPA said:

“I am delighted to pass on the torch to Antonio D’Amato this year. He brings a wealth of experience to the role. Our biggest challenge is to engage constructively on the complex Packaging and Packaging Waste Regulation file. We will continue to make the case for recyclable, renewable paper-based packaging at the heart of Europe’s circular economy and ensure that policies are based on science and evidence.”

Matti Rantanen, Director General of the European Paper Packaging Alliance added:

“I am excited to join EPPA and work to promote recyclable and renewable paper packaging as a solution to achieve a fully circular economy. Reviewing the EU’s packaging and packaging waste rules is crucial, yet it must be done rationally and in accordance with scientific evidence. EPPA’s studies have shown that in quick-service restaurants, both for in-store consumption and takeaway services, single-use paper packaging is simply better for the environment, the economy and consumer health. I am dedicated to getting this message across. As we continue to feel the effects of climate change and of the global economic crisis everyday, EPPA will continue to offer facts and evidence that should be acknowledged by policy makers.”

ENDS

About EPPA:

The European Paper Packaging Alliance is a non-for-profit food and foodservice packaging association. The priorities of the Alliance are to find concrete solutions to increase recycling and to reduce carbon emissions of food and foodservice packaging without compromising food safety and human health protection. More information is available here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roxana Moldovan

0032495219394

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye